Compare · RGC vs XXII
RGC vs XXII
Side-by-side comparison of Regencell Bioscience Holdings Limited (RGC) and 22nd Century Group Inc. (XXII): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RGC and XXII operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RGC is the larger of the two at $10.58B, about 31.9x XXII ($332.0M).
- Over the past year, RGC is up 34.4% and XXII is down 99.8% - RGC leads by 134.2 points.
- RGC has been more active in the news (6 items in the past 4 weeks vs 2 for XXII).
- XXII has more recent analyst coverage (4 ratings vs 0 for RGC).
- Company
- Regencell Bioscience Holdings Limited
- 22nd Century Group Inc.
- Price
- $21.58+7.42%
- $0.52+9.16%
- Market cap
- $10.58B
- $332.0M
- 1M return
- -32.29%
- -27.02%
- 1Y return
- +34.37%
- -99.79%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- AMEX
- IPO
- 2021
- News (4w)
- 6
- 2
- Recent ratings
- 0
- 4
22nd Century Group Inc.
22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
Latest RGC
- SEC Form 4 filed by Director Lo William Wing Yan Dr
- SEC Form 4 filed by Director Hui Evana Yee Wah
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 424B5 filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
Latest XXII
- 22nd Century Group (Nasdaq: XXII) Launches Pinnacle VLN® Trial in California, Opening Another Major New State for Reduced-Nicotine Cigarettes
- 22nd Century Group (Nasdaq: XXII) Expands High-Margin Pinnacle Platform With Launch of Pinnacle Pure at Major U.S. Retailers
- 22nd Century Group (Nasdaq: XXII) Ignites Major VLN® Retail Expansion in Metro New York and Northern New Jersey Under Pinnacle Brand
- 22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review
- SEC Form 10-Q filed by 22nd Century Group Inc.
- 22nd Century Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- 22nd Century Group Reports First Quarter 2026 Financial Results
- 22nd Century Group to Announce First Quarter 2026 Results on May 7, 2026
- 22nd Century Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by 22nd Century Group Inc.